Your idea

Our expertise

One goal

 

How we can help

Who we are

Our experts have supported multiple organizations in successfully bringing innovative drugs, medical devices, and combination products to the market. With an average of 20-40 years of experience in various fields of life sciences, the current team includes highly skilled professionals with specific expertise required for successful product development. Together with our partner consultants, we join forces to innovate and empower you to grow.

Your idea

Our expertise

One goal

Who we are

Our experts have supported multiple organizations in successfully bringing innovative drugs, medical devices, and combination products to the market. With an average of 20-40 years of experience in various fields of life sciences, the current team includes highly skilled professionals with specific expertise required for successful product development. Together with our partner consultants, we join forces to innovate and empower you to grow.

Management

Our goal is to empower the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare worldwide.

Vanja / Head of Clinical Operations

Pascal / CEO

Mohamed / Head of Commercial Operations

Management

Our goal is to empower the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare worldwide.

Portrait of Pascal Winnen, CEO at Hemex AG

Pascal
CEO

Portrait of Vanja Ivancevic, Hemex AG

Vanja
Head of Clinical Operations

Portrait of Mohamed Hussien, Hemex AG

Mohamed
Head of Commercial Operations

Paul

Ricardo

Portrait of Pascal Winnen, CEO at Hemex AG

Pascal

Our story

2022

ISO 9001 & 13485

HEMEX is ISO 9001:2015 and ISO 13485:2016 Quality Management System certified.

ICH-GCP E6 Certified

HEMEX team successfully passes and obtains the ICH-GCP E6 (Good Clinical Practice) certification.

Flourish Business

Office space in Liestal is expanded, and CRO customer base in Europe and UK is strongly increased.

Successful closing of Series D1

HEMEX completes first closing of another fundraising round, bringing the total to CHF 10 million.

2021

Successful closing of Series C1

HEMEX starts fundraising, to allow investors to co-invest with us in promising early-stage life science companies.

Oversubscribed Series C2

HEMEX successfully completes an oversubscribed Series C at 7.1 million to further grow the company’s portfolio.

2019

New Office Building

Relocation to larger office space at Kasernenstrasse 30, in Liestal, Switzerland to accommodate growing team.

2018

Subsidiary USA

HEMEX opens a 100% subsidiary in Bethesda, MD (currently in Orlando, FL) to expand market reach in the US.

Series B Fundraising

Financing round “Series B” by the Founders to secure additional funding to expand HEMEX operations and make first investments in early-stage start-ups.

2017

Subsidiary Germany

HEMEX opens a 100% subsidiary in Lörrach, Germany to expand market reach in the EU.

GMP Licensed

HEMEX receives Good Manufacturing Practice (GMP) license from the Health Authority of Baden-Württemberg, Germany.

2015

Incorporation

HEMEX is incorporated in Baselland in Liestal, Switzerland.

GDP Licensed

HEMEX receives Good Distribution Practice (GDP) license by Swissmedic.

2011

Idea is born

Three senior pharmaceutical executives have the idea of founding a “Healthcare Management Expert” CRO with the goal of bringing innovative pharmaceuticals, medical devices, and in vitro diagnostics to the market. Pretty soon, a first customer hires the team, resulting in the first drug approved in Europe only 4 years later.

Our story

ISO 9001 & 13485

HEMEX is ISO 9001:2015 and ISO 13485:2016 Quality Management System certified.

ICH-GCP E6 Certified

HEMEX team successfully passes and obtains the ICH-GCP E6 (Good Clinical Practice) certification.

Flourish Business

Office space in Liestal is expanded, and CRO customer base in Europe and UK is strongly increased.

Successful closing of Series D1

HEMEX completes first closing of another fundraising round, bringing the total to CHF 10 million.

Successful closing of Series C1

HEMEX starts fundraising, to allow investors to co-invest with us in promising early-stage life science companies.

Oversubscribed Series C2

HEMEX successfully completes an oversubscribed Series C at 7.1 million to further grow the company’s portfolio.

New Office Building

Relocation to larger office space at Kasernenstrasse 30, in Liestal, Switzerland to accommodate growing team.

Subsidiary USA

HEMEX opens a 100% subsidiary in Bethesda, MD (currently in Orlando, FL) to expand market reach in the US.

Series B Fundraising

Financing round “Series B” by the Founders to secure additional funding to expand HEMEX operations and make first investments in early-stage start-ups.

Subsidiary Germany

HEMEX opens a 100% subsidiary in Lörrach, Germany to expand market reach in the EU.

GMP Licensed

HEMEX receives Good Manufacturing Practice (GMP) license from the Health Authority of Baden-Württemberg, Germany.

Incorporation

HEMEX is incorporated in Baselland in Liestal, Switzerland.

GDP Licensed

HEMEX receives Good Distribution Practice (GDP) license by Swissmedic.

Idea is born

Three senior pharmaceutical executives have the idea of founding a “Healthcare Management Expert” CRO with the goal of bringing innovative pharmaceuticals, medical devices, and in vitro diagnostics to the market. Pretty soon, a first customer hires the team, resulting in the first drug approved in Europe only 4 years later.

HEMEX in the media

Investoren von Innovationen überzeugen

Bei HEMEX erhalten Startups ein Podium, um ihre fortgeschrittenen Health Care-Innovationen potenziellen Investoren ausführlich und in kleiner Runde vorzustellen. Vom Implantate-System zur Behandlung chronischer Lymphödem-Schwellungen über die Methode zur Selbstmessung von Schlafstörungen und Therapie für Patienten mit multiresistenten Krebserkrankungen bis zur Technologie für die Ursachenbekämpfung von Paradontitis – vier erfolgversprechende Jungunternehmen nahmen letztes Jahr am ersten physischen Pitch-Event seit Ausbruch der Pandemie in Liestal teil und stellten sich kritischen Fragen.

HEMEX erhält 7,1 Millionen Franken

Mit dem frischen Kapital will HEMEX, Partner der Standortförderung Basel Area Business & Innovation, Erstinvestitionen in die Frühphase von Start-ups finanzieren, die in den Life Sciences tätig sind. Außerdem plant das in Liestal ansässige Unternehmen, neue Team-Mitglieder für klinische Aktivitäten, Qualitätssicherung und Regulierungsangelegenheiten zu rekrutieren.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX gewinnt Schweizer Investoren

Eine Gruppe erfahrener Schweizer Unternehmer und privater Investoren hat sich bei einer nach Unternehmensangaben signifikant überzeichneten Finanzierungsrunde an Hemex beteiligt. Mit dem frischen Kapital will der Biotech-Inkubator das weltweite Wachstum beschleunigen.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.

HEMEX in the media

Investoren von Innovationen überzeugen

Bei HEMEX erhalten Startups ein Podium, um ihre fortgeschrittenen Health Care-Innovationen potenziellen Investoren ausführlich und in kleiner Runde vorzustellen. Vom Implantate-System zur Behandlung chronischer Lymphödem-Schwellungen über die Methode zur Selbstmessung von Schlafstörungen und Therapie für Patienten mit multiresistenten Krebserkrankungen bis zur Technologie für die Ursachenbekämpfung von Paradontitis – vier erfolgversprechende Jungunternehmen nahmen letztes Jahr am ersten physischen Pitch-Event seit Ausbruch der Pandemie in Liestal teil und stellten sich kritischen Fragen.

HEMEX erhält 7,1 Millionen Franken

Mit dem frischen Kapital will HEMEX, Partner der Standortförderung Basel Area Business & Innovation, Erstinvestitionen in die Frühphase von Start-ups finanzieren, die in den Life Sciences tätig sind. Außerdem plant das in Liestal ansässige Unternehmen, neue Team-Mitglieder für klinische Aktivitäten, Qualitätssicherung und Regulierungsangelegenheiten zu rekrutieren.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX gewinnt Schweizer Investoren

Eine Gruppe erfahrener Schweizer Unternehmer und privater Investoren hat sich bei einer nach Unternehmensangaben signifikant überzeichneten Finanzierungsrunde an Hemex beteiligt. Mit dem frischen Kapital will der Biotech-Inkubator das weltweite Wachstum beschleunigen.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.